Merck & Co., Inc.
MarketLine (a Datamonitor Company)
08 Jan 2014
Available for Immediate Download
Merck & Co., Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Merck & Co., Inc. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Merck & Co., Inc. in the form of a SWOT analysis - An in-depth view of the business model of Merck & Co., Inc. including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Merck & Co., Inc. - Intelligence on Merck & Co., Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Merck & Co., Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Merck & Co. (or ‘the company’), known as Merck Sharp & Dohme (MSD) outside the US and Canada, is one of the leading healthcare companies in the world. The company is engaged in the research, development, manufacture and marketing of prescription pharmaceuticals, vaccines, biologic therapies, and consumer care and animal health products. It operates in more than 140 countries. Merck & Co. is headquartered in Whitehouse Station, New Jersey, and employed about 83,000 people as of December 31, 2012. The company recorded revenues of $47,267 million during the financial year ended December 2012 (FY2012), a decrease of 1.6% over FY2011. The operating profit of the company was $8,739 million in FY2012, an increase of 19.2% over FY2011. The net profit was $6,168 million in FY2012, a decrease of 1.7% over FY2011. Reasons to Purchase: - Gain understanding of Merck & Co., Inc. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Merck & Co., Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Merck & Co., Inc.’s business structure, strategy and prospects